RLAY News and Press, Relay Therapeutics Inc. From 03/10/21

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced that preclinical data for RLY-4008, a po...

Relay Therapeutics stock has fallen from a price of $62 in mid-January, to $41.3 at the time of writing. The data-driven drug developer is slowly becoming a clinical-stage biotech with three assets in development - one in partnership with Genentech. Its targets are attractive - th...

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on Thursday, February 11, 2021 at 3:30 p.m. ET. The fireside chat will be webcast live and may be a...

Neoleukin is a leader in de novo drug design. The company's lead asset was recently put on clinical hold, pending more dosing data, creating a window to buy the stock. The company has the platform potential to expand their pipeline to a wide-range of protein therapeutics for cancer an...

The following slide deck was published by Relay Therapeutics, Inc. in conjunction with this event. For further details see: Relay Therapeutics (RLAY) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 4:30 p.m. ET. The presentation will be webcast live and may be accessed from the Investor ...

Relay Therapeutics (RLAY) has signed a worldwide license and collaboration agreement with Genentech, a member of the Roche Group, for the development and commercialization of RLY-1971, a potent inhibitor of SHP2 to expand into multiple combination studies including with Genentech’s inv...

Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors Relay Therapeutics will receive $75 million upfront and is eligible to receive an additional $25 million in near-term payments and $695 million in additional potential milestones, plus royalties on ...

Kinnate Biopharma (KNTE) has raised the proposed deal size for its upcoming IPO.The company now plans to raise $213M by offering 11.5M shares at a price range of $18 to $19 vs. original offering of 10M shares at a range of $16 to $18.Kinnate is focused on the discovery and development of...

Kinnate Biopharma aims to raise $170 million in an IPO. The firm is developing kinase inhibitor-based treatment candidates for various cancers. KNTE has produced promising results in preclinical studies, but is still extremely high risk; the IPO may be more suited to long-term hol...